TSC2 oncogenic variants
About
Gene context: TSC2
Biomarker Type: Somatic Variant
Present: True
Chromosome: 16
Requires Oncogenic: True
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | TSC2 oncogenic variants | Renal Angiomyolipoma | Everolimus | |
| FDA (1) | TSC2 oncogenic variants | Anaplastic Thyroid Cancer | Everolimus |